Once you start testing in trials you often uncover some unknown new information about the disease and how the treatment might best be applied. Illness tends to be a spectrum with different causes such as DNA and environmental variables, concomitant diseases and predisposing conditions such as viral infections.
The DME trial result might even have been different if the combination was with Lucentis rather than Eylea, or patient selection had been different. If we had complete understanding of the disease and the treatments it would all make sense. For now, the results are part of a puzzle to be unravelled
Ann: Opthea Reports Positive Ph2a Trial Results of OPT-302 in DME, page-110
-
- There are more pages in this discussion • 15 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add OPT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
85.0¢ |
Change
0.025(3.03%) |
Mkt cap ! $1.046B | |||
| Open | High | Low | Value | Volume |
| 82.0¢ | 87.0¢ | 81.0¢ | $2.966M | 3.483M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 3000 | 84.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 85.0¢ | 980 | 1 |
View Market Depth
| Last trade - 16.10pm 04/10/2024 (20 minute delay) ? |
| OPT (ASX) Chart |